Bile acid metabolism disorders encompass a range of rare, yet clinically significant, genetic conditions that disrupt the normal synthesis and regulation of bile acids by the liver. These conditions, ...

FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that they have entered into a definitive ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral ...

• Advances Travere’s strategy to deliver new treatment standards from its pipeline of innovative medicines for rare diseases and strengthens financial foundation • Expands Mirum’s leadership in rare ...

Liver is the major organ for metabolism of sulfur amino acids (methionine, cysteine, taurine) and expresses high levels of sulfur amino acid synthesis and metabolising enzymes. Dietary intake, ...

FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the completion of Mirum’s previously ...

• Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments• Mirum has acquired Travere’s rights and assets related to Cholbam® and ...